Home › B-Cell Lymphoma › Nebraska › Omaha
B-Cell Lymphoma clinical trials in Omaha, NE
5 studies for B-Cell Lymphoma are looking for participants at sites in and around Omaha (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
RecruitingPhase 3
- Nebraska Cancer Specialists, Omaha
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
RecruitingPhase 1/2
- University of Nebraska Medical Center, Omaha
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
RecruitingPhase 1
- University of Nebraska Medical Center, Omaha
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RecruitingPhase 3
- University of Nebraska Medical Center (UNMC), Omaha
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
RecruitingPhase 1/2
- Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha
B-Cell Lymphoma trials in other cities
- New York City, NY19 studies
- Houston, TX16 studies
- Chicago, IL12 studies
- Philadelphia, PA11 studies
- Nashville, TN11 studies
- Rochester, MN10 studies
- Baldwin Park, CA9 studies
- Milwaukee, WI9 studies
- Cleveland, OH9 studies
- Salt Lake City, UT8 studies
- Boston, MA8 studies
- Pittsburgh, PA7 studies
Other studies in Omaha
- Prostate Cancer27 studies
- Non-Small Cell Lung Cancer24 studies
- Breast Cancer22 studies
- Colorectal Cancer18 studies
- Cancer (all types)18 studies
- Multiple Myeloma16 studies
- Non-Hodgkin Lymphoma14 studies
- Ovarian Cancer14 studies
- Pancreatic Cancer14 studies
- Head and Neck Squamous Cell Carcinoma13 studies
- Heart Failure13 studies
- Metastatic Cancer13 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.